Arte SheetsLearn. Try. Understand.

Clinical Pharmacokinetics & Biopharmaceutics

Oral Bateman pharmacokinetics: peak time and bioavailability

Explore dose-normalized oral-to-IV AUC, time to peak and peak concentration for a one-compartment first-order model.

What the model assumes

The Bateman function describes a one-compartment model with first-order absorption and elimination after a single extravascular dose. With positive absorption rate k_a, elimination rate k_e, model distribution volume V and model bioavailability fraction F, concentration is F × Dose × k_a / [V × (k_a − k_e)] × [exp(−k_e t) − exp(−k_a t)] when the rate constants differ. The model and synthetic examples below are educational and do not determine dosing.

For comparable oral and intravenous studies, the dose-normalized AUC ratio estimates absolute bioavailability: (AUC_oral × Dose_IV) / (AUC_IV × Dose_oral). Interpretation depends on the study design, sampling, matching units and comparable clearance. An observed estimate above 1 can arise and warrants investigation of assumptions; do not confuse it with a bioequivalence acceptance limit.

Calculate a dose-normalized AUC ratio

Enter positive oral dose and IV dose in the same units, and AUC values in matching units. An ideal bioavailable fraction is between zero and one, but this worksheet reports the observed ratio without capping it or deciding bioequivalence.

=IF(COUNT(B2:B5)<>4,"Enter dose and AUC inputs",IF(OR(B2<=0,B3<=0,B4<=0,B5<=0),"Dose and AUC must be positive",ROUND((B3*B4)/(B5*B2),4)))

Calculate time to peak

For unequal positive rates t_max = ln(k_a/k_e)/(k_a−k_e). When the rates are equal, the continuous limit is 1/k_e. To avoid unstable subtraction, the worksheet uses that limit when the absolute rate difference is at most 10⁻⁸ times the larger rate. The peak-time calculation needs only the two rate constants.

=IF(COUNT(B7:B8)<>2,"Enter both rate constants",IF(OR(B7<=0,B8<=0),"Rates must be positive",ROUND(IF(ABS(B7-B8)<=0.00000001*MAX(B7,B8),1/B8,LN(B7/B8)/(B7-B8)),4)))

Calculate peak concentration and inspect rate ordering

In this model C_max = (F × Dose / V) × exp(−k_e × t_max), using the unrounded peak time and AUC ratio. It assumes the same model and comparable oral and IV clearance; real concentration profiles need not follow this simplified model. A slower absorption rate can produce flip-flop behavior in the terminal phase, but rate ordering alone is not an observed diagnosis.

For a self-consistent fictional example: oral dose 400 mg, oral AUC 60 mg·h/L, IV dose 200 mg, IV AUC 40 mg·h/L, V = 20 L, k_a = 1/h and k_e = 0.25/h. Then F = 0.75, t_max ≈ 1.8484 h and C_max ≈ 9.4494 mg/L. Here k_e × V = 5 L/h is consistent with IV dose/AUC = 5 L/h.

=IF(NOT(ISNUMBER(E2)),E2,IF(NOT(ISNUMBER(E3)),E3,IF(COUNT(B6)<>1,"Enter volume",IF(B6<=0,"Volume must be positive",ROUND((B3*B4)/(B5*B6)*EXP(-B8*IF(ABS(B7-B8)<=0.00000001*MAX(B7,B8),1/B8,LN(B7/B8)/(B7-B8))),4)))))

Bioavailability and bioequivalence are different questions

Absolute bioavailability compares dose-normalized exposure after an extravascular route with intravenous exposure. Bioequivalence is a statistical comparison of products; the FDA guidance describes confidence-interval criteria for particular study endpoints. Its 80%–125% bounds are not a maximum permissible value for an individual absolute-bioavailability estimate.

Try the example

Use the original values or change them to test your understanding.

Further reading